OBJECTIVE: Recent meta-analysis of antibiotic therapy for postpartum endometritis found that clindamycin and gentamicin were not associated with increased risk for adverse outcomes, however data was limited. We sought to describe the risk of Clostridium difficile infection (CDI) associated with clindamycin and acute kidney injury (AKI) associated with gentamicin during delivery hospitalization. STUDY DESIGN: An administrative inpatient database that includes medications was analyzed to evaluate outcomes in women admitted for delivery from January 2006 to March 2015. Primary outcomes were CDI and AKI. CDI was compared between women receiving clindamycin (+/-other antibiotics) and women receiving antibiotics other than clindamycin. AKI was compared between women receiving gentamicin (+/-other antibiotics), women receiving other antibiotics, and women receiving no antibiotics. Unadjusted and adjusted log linear models analyzing the role of patient demographics, mode of delivery and hospital-level characteristics were created evaluating the risk for CDI and AKI. RESULTS: 5,657,523 women admitted for delivery hospitalization were included. Of these, 266,505 (4.7%) received clindamycin and 166,128 (2.9%) received gentamicin. CDI was diagnosed in 0.04% of women receiving clindamycin. Compared to women receiving other antibiotics, clindamycin was associated with a nearly three-fold increased risk of CDI (RR 2.93, 95% CI 2.36, 3.65). AKI was diagnosed in 0.24% of women receiving gentamicin. Gentamicin was associated with a three-fold risk of AKI (RR 3.01, 95% CI 2.70, 3.34) compared to women receiving other antibiotics, and a 17-fold risk of AKI compared to women receiving no antibiotics (RR 17.0, 95% CI 14.7, 19.6). In adjusted analyses, these associations retained significance (Table 1 and 2). Other risk factors identified for both CDI and AKI included comorbidity, cesarean delivery, and hospital size. Additional risks for AKI were advanced maternal age, and black race. CONCLUSION: Receipt of clindamycin was associated with significantly increased risk of CDI and gentamicin with a significantly increased risk of AKI. Though absolute risk is low, alternative treatment regimens for postpartum endometritis may be considered in patients most at risk for these complications.
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Poster Session III OBJECTIVE: Universal antenatal screening and intrapartum antibiotic prophylaxis are recommended to prevent perinatal Group B streptococcus (GBS) disease. Vancomycin use is recommended only for women at high risk for beta-lactam anaphylaxis with GBS cultures resistant to clindamycin and erythromycin. We sought to evaluate the use of vancomycin in GBS positive women undergoing vaginal delivery and describe trends over time. STUDY DESIGN: An administrative inpatient database that includes medications was analyzed to evaluate antibiotic use in women admitted for delivery from January 2006 to March 2015. Women were included if they had a vaginal delivery. Primary outcome was receipt of vancomycin by GBS status. Secondary outcomes included trends in vancomycin use, trends in antibiotic use overall among GBS positive women, and types of antibiotics used in this setting. RESULTS: Of 3,758,149 women admitted for vaginal delivery, 655,351 (17.4%) were coded as GBS positive. Of these, 13,215 (2.02%) received vancomycin during their hospitalization. Among GBS positive women the proportion who received vancomycin increased significantly from 0.76% to 3.14% over the study period; use of vancomycin also increased concurrently among GBS negative women from 0.15% to 0.37% (Figure 1) . Overall, 528, 335 (80.4%) of GBS positive women received any antibiotic during their hospitalization and the proportion receiving antibiotics decreased significantly from 84.2% in 2006 to 76.0% in 2015. The most common antibiotics administered to GBS positive women undergoing vaginal delivery were penicillin, ampicillin, and erythromycin (Table 1) .
CONCLUSION: Use of vancomycin among GBS positive women increased over the study period. This trend may be due to a combination of (i) increased penicillin allergies, (ii) increased antibiotic resistance, and (iii) less frequent testing of antibiotic sensitivities for penicillin-allergic patients. Hospital level systems improvements may be needed to increase obtainment of sensitivities for penicillinallergic women and reduce unnecessary use of this broad spectrum antibiotic.
625 Impact of excess weight gain on risk of postpartum infection in class III obesity OBJECTIVE: Obesity increases postpartum infectious morbidity. However, the impact of gestational weight gain on that risk remains unclear, especially in morbidly obese women. We aimed to assess the impact of gestational weight gain >20 pounds (lbs) (more than Institute of Medicine (IOM) recommendations) on postpartum infectious morbidity in morbidly obese women. STUDY DESIGN: Retrospective cohort of term, non-anomalous singleton pregnancies with maternal body mass index (BMI) 40 at a single institution from 2013-2017. Pregnancies with multiple gestation, late entry to care, and missing weight gain data are excluded. Primary outcome is a composite of postpartum infection (endomyometritis, urinary tract, respiratory, wound) documented >24 hours and <6 weeks postpartum. Secondary outcomes include individual components of composite infection, wound complication, readmission, and blood transfusion. Bivariate statistics compared
